Mansour Gergi, M.D.
Assistant Professor of Medicine, Division of Hematology and Oncology
Hematologist and Medical Oncologist, UVM Health Network
89 Beaumont Ave
Given Building
Larner College of Medicine
Burlington, VT 05405
United States
- M.D., Lebanese University Faculty of Medical Sciences
- M.D., Educational Commission for Foreign Medical Graduates
University of Vermont Cancer Center
Division of Hematology and Oncology
Vermont Center for Cardiovascular and Brain Health
BIO
Mansour Gergi, MD is a hematologist and medical oncologist at the UVM Medical Center, and an assistant professor of medicine at the Larner College of Medicine.
Dr. Gergi manages a variety of conditions including lymphoma, myeloma, MDS and AML, autologous stem cell transplant and CART therapy. c. His research interests include bleeding and cardiovascular care in patients with cancer, especially with hematologic malignancies. His published research can be found here.
Dr. Gergi chose his specialty because he appreciates the long-term relationships he builds with his patients. He loves interacting with patients, and his mission is always to make a positive impact in their lives. He tries to take the time to listen to his patients, and does his best to explain their disease and treatment to them so they can fully understand their condition, and help him make the decisions that are best for them. He always tells his patients, “You are in the driver’s seat – I help you by making recommendations based on my knowledge, but we make decisions together.”
Dr. Gergi is interested in bleeding as a complication in cancer patients and how that affects care delivery either in the case antithrombotic use for cardiovascular indications or for the treatment of venous, thromboembolic disease. He uses the electronic health record to develop algorithms that allow identification of rare events--such as bleeding--in large cohorts of patients without the need for manual chart review.
Dr. Gergi's maintains memberships in the following professional societies:
- American Society of Hematology
- International Society of Thrombosis and Hemostasis
Dr. Gergi's postdoctoral training
Residency in internal medicine, Roger Williams University
Fellowship in Hematology and Medical Oncology, University of Vermont Health Network
Dr. Gergi's UVM Health provider page
Dr. Gergi's UVM Cancer Center Member page
Publications
Dr. Gergi's publications on PubMed
Awards and Achievements
Recipient of the Green and Gold early career Professorship from the Department of Medicine at the Larner College of Medicine at the University of Vermont for his work on bleeding in cancer patients.
Area(s) of expertise
Clinical Specialty: Malignant hematology
Research Focus: Bleeding and cardiovascular care in individuals with cancer
Dr. Gergi's Recent Publications
Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial. Sholzberg M, Tang GH, Rahhal H, AlHamzah M, Kreuziger LB, Áinle FN, Alomran F, Alayed K, Alsheef M, AlSumait F, Pompilio CE, Sperlich C, Tangri S, Tang T, Jaksa P, Suryanarayan D, Almarshoodi M, Castellucci LA, James PD, Lillicrap D, Carrier M, Beckett A, Colovos C, Jayakar J, Arsenault MP, Wu C, Doyon K, Andreou ER, Dounaevskaia V, Tseng EK, Lim G, Fralick M, Middeldorp S, Lee AYY, Zuo F, da Costa BR, Thorpe KE, Negri EM, Cushman M, Jüni P; RAPID trial investigators. BMJ. 2021 Oct 14;375:n2400. doi: 10.1136/bmj.n2400. PMID: 34649864 Free PMC article. Clinical Trial.
Thromboinflammation response to tocilizumab in COVID-19. Gergi M, Cushman M, Littenberg B, Budd RC. Res Pract Thromb Haemost. 2020 Oct 18;4(8):1262-1268. doi: 10.1002/rth2.12436. eCollection 2020 Nov. PMID: 33043232 Free PMC article.
Palliative Care Issues for Transfusion-Dependent Patients #359. Gergi M, Soriano-Pisaturo MA. J Palliat Med. 2018 Sep;21(9):1359-1360. doi: 10.1089/jpm.2018.0347. PMID: 30207884 Review. No abstract available
Thrombo-inflammatory biomarkers and D-dimer in a biracial cohort study. Kamin Mukaz D, Gergi M, Koh I, Zakai NA, Judd SE, Sholzberg M, Baumann Kreuziger L, Freeman K, Colovos C, Olson NC, Cushman M. Res Pract Thromb Haemost. 2021 Dec 7;5(8):e12632. doi: 10.1002/rth2.12632. eCollection 2021 Dec. PMID: 34934895 Free PMC article.
Viscoelastic hemostasis assays in septic, critically ill coronavirus disease 2019 patients: a practical guide for clinicians. Gergi M, Goodwin A, Freeman K, Colovos C, Volod O. Blood Coagul Fibrinolysis. 2021 Apr 1;32(3):225-228. doi: 10.1097/MBC.0000000000000999. PMID: 33443923 Free PMC article. Review.
Nivolumab-Induced Thrombotic Thrombocytopenic Purpura in a Patient with Anal Squamous Cell Carcinoma: A Lesson on Hematologic Toxicity from Immunotherapy. Gergi M, Landry KK, Ades S, Barry M, Zakai NA, Herrera DA. Oncologist. 2020 Dec;25(12):1009-1012. doi: 10.1002/onco.13553. Epub 2020 Oct 23. PMID: 33017484 Free PMC article. Review.
Bio
Mansour Gergi, MD is a hematologist and medical oncologist at the UVM Medical Center, and an assistant professor of medicine at the Larner College of Medicine.
Dr. Gergi manages a variety of conditions including lymphoma, myeloma, MDS and AML, autologous stem cell transplant and CART therapy. c. His research interests include bleeding and cardiovascular care in patients with cancer, especially with hematologic malignancies. His published research can be found here.
Dr. Gergi chose his specialty because he appreciates the long-term relationships he builds with his patients. He loves interacting with patients, and his mission is always to make a positive impact in their lives. He tries to take the time to listen to his patients, and does his best to explain their disease and treatment to them so they can fully understand their condition, and help him make the decisions that are best for them. He always tells his patients, “You are in the driver’s seat – I help you by making recommendations based on my knowledge, but we make decisions together.”
Dr. Gergi is interested in bleeding as a complication in cancer patients and how that affects care delivery either in the case antithrombotic use for cardiovascular indications or for the treatment of venous, thromboembolic disease. He uses the electronic health record to develop algorithms that allow identification of rare events--such as bleeding--in large cohorts of patients without the need for manual chart review.
Dr. Gergi's maintains memberships in the following professional societies:
- American Society of Hematology
- International Society of Thrombosis and Hemostasis
Dr. Gergi's postdoctoral training
Residency in internal medicine, Roger Williams University
Fellowship in Hematology and Medical Oncology, University of Vermont Health Network
Dr. Gergi's UVM Health provider page
Dr. Gergi's UVM Cancer Center Member page
Publications
Awards and Achievements
Recipient of the Green and Gold early career Professorship from the Department of Medicine at the Larner College of Medicine at the University of Vermont for his work on bleeding in cancer patients.
Areas of Expertise
Clinical Specialty: Malignant hematology
Research Focus: Bleeding and cardiovascular care in individuals with cancer
Dr. Gergi's Recent Publications
Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial. Sholzberg M, Tang GH, Rahhal H, AlHamzah M, Kreuziger LB, Áinle FN, Alomran F, Alayed K, Alsheef M, AlSumait F, Pompilio CE, Sperlich C, Tangri S, Tang T, Jaksa P, Suryanarayan D, Almarshoodi M, Castellucci LA, James PD, Lillicrap D, Carrier M, Beckett A, Colovos C, Jayakar J, Arsenault MP, Wu C, Doyon K, Andreou ER, Dounaevskaia V, Tseng EK, Lim G, Fralick M, Middeldorp S, Lee AYY, Zuo F, da Costa BR, Thorpe KE, Negri EM, Cushman M, Jüni P; RAPID trial investigators. BMJ. 2021 Oct 14;375:n2400. doi: 10.1136/bmj.n2400. PMID: 34649864 Free PMC article. Clinical Trial.
Thromboinflammation response to tocilizumab in COVID-19. Gergi M, Cushman M, Littenberg B, Budd RC. Res Pract Thromb Haemost. 2020 Oct 18;4(8):1262-1268. doi: 10.1002/rth2.12436. eCollection 2020 Nov. PMID: 33043232 Free PMC article.
Palliative Care Issues for Transfusion-Dependent Patients #359. Gergi M, Soriano-Pisaturo MA. J Palliat Med. 2018 Sep;21(9):1359-1360. doi: 10.1089/jpm.2018.0347. PMID: 30207884 Review. No abstract available
Thrombo-inflammatory biomarkers and D-dimer in a biracial cohort study. Kamin Mukaz D, Gergi M, Koh I, Zakai NA, Judd SE, Sholzberg M, Baumann Kreuziger L, Freeman K, Colovos C, Olson NC, Cushman M. Res Pract Thromb Haemost. 2021 Dec 7;5(8):e12632. doi: 10.1002/rth2.12632. eCollection 2021 Dec. PMID: 34934895 Free PMC article.
Viscoelastic hemostasis assays in septic, critically ill coronavirus disease 2019 patients: a practical guide for clinicians. Gergi M, Goodwin A, Freeman K, Colovos C, Volod O. Blood Coagul Fibrinolysis. 2021 Apr 1;32(3):225-228. doi: 10.1097/MBC.0000000000000999. PMID: 33443923 Free PMC article. Review.
Nivolumab-Induced Thrombotic Thrombocytopenic Purpura in a Patient with Anal Squamous Cell Carcinoma: A Lesson on Hematologic Toxicity from Immunotherapy. Gergi M, Landry KK, Ades S, Barry M, Zakai NA, Herrera DA. Oncologist. 2020 Dec;25(12):1009-1012. doi: 10.1002/onco.13553. Epub 2020 Oct 23. PMID: 33017484 Free PMC article. Review.